# Safety and Antiviral Activity of a Monoclonal Hepatitis B Antibody (The SAMBA Study)

> **NCT06668727** · PHASE1 · RECRUITING · sponsor: **Aarhus University Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Hepatitis B

## Interventions

- **DRUG:** HepB mAb19

## Key facts

- **NCT ID:** NCT06668727
- **Lead sponsor:** Aarhus University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-26
- **Primary completion:** 2027-08-26
- **Final completion:** 2027-08-26
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06668727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06668727, "Safety and Antiviral Activity of a Monoclonal Hepatitis B Antibody (The SAMBA Study)". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT06668727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*